Company Benitec Biopharma Inc. Deutsche Boerse AG
Equities
BJ9
US08205P2092
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 EUR | -2.70% | -.--% | -.--% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 16-09-30 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-28 |
Megan Boston
CMP | Compliance Officer | 52 | 16-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 13-03-31 |
Edward Smith
BRD | Director/Board Member | 53 | 20-04-13 |
Peter Francis
BRD | Director/Board Member | 68 | 06-01-31 |
Jerel Banks
CEO | Chief Executive Officer | 49 | 16-09-30 |
Megan Boston
CMP | Compliance Officer | 52 | 16-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,367,485 | 8,497,929 ( 90.72 %) | 0 | 90.72 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- BNTC Stock
- BJ9 Stock
- Company Benitec Biopharma Inc.